Management of SIADH
For SIADH, fluid restriction to 1 L/day is the cornerstone of treatment in asymptomatic or mildly symptomatic patients, while severely symptomatic patients (seizures, coma, altered mental status) require immediate hypertonic saline (3% NaCl) with a target correction of 6 mmol/L over 6 hours or until symptoms resolve. 1
Initial Diagnostic Workup
Before initiating treatment, confirm SIADH diagnosis with:
- Serum and urine osmolality (serum osmolality low, urine osmolality inappropriately concentrated) 1
- Urine sodium (typically >40 mmol/L) 1
- Uric acid levels 1
- Volume status assessment (must be euvolemic - rule out hypovolemia and hypervolemia) 1
Important caveat: Obtaining ADH and natriuretic peptide levels is NOT supported by evidence and should not delay treatment 1. Physical examination findings combined with basic laboratory studies are sufficient for diagnosis 1.
Treatment Algorithm Based on Symptom Severity
Severe Symptoms (Seizures, Coma, Mental Status Changes)
Immediate hypertonic saline (3% NaCl) is indicated: 1
- Transfer to ICU setting 1
- Target: Correct 6 mmol/L over 6 hours OR until severe symptoms resolve 1
- Critical safety limit: Total correction must NOT exceed 8 mmol/L in 24 hours 1
- Monitor serum sodium every 2 hours 1
- Calculate sodium deficit: Desired increase in Na (mEq) × (0.5 × ideal body weight in kg) 1
Once severe symptoms resolve, transition to less aggressive therapy (see mild symptoms protocol below) 1
Mild Symptoms (Nausea, Vomiting, Headache, Aches)
- Transfer to intermediate care unit 1
- Fluid restriction to 1 L/day 1
- Monitor serum sodium every 4 hours initially 1
- Daily weights and strict intake/output monitoring 1
Asymptomatic or Refractory Cases
First-line: Fluid restriction 1 L/day 1
Second-line options if fluid restriction fails (which occurs in approximately 50% of cases): 2
- Oral salt tablets (NaCl 100 mEq three times daily) 1
- High protein diet (increases urea production, promoting water excretion) 1
- Urea 40g in 100-150 mL normal saline every 8 hours for 1-2 days 1
- Loop diuretics (furosemide or ethacrynic acid) with sodium supplementation - note that sodium supplements were needed in 9 of 11 patients and potassium replacement in 7 patients in one study 1
- Tolvaptan (vasopressin-2 receptor antagonist) - produces mean rate of sodium change of 3.0 mEq/L/day, comparable to hypertonic saline 2, 3
Critical Safety Parameters
Maximum correction rates to prevent osmotic demyelination syndrome: 1
- Do NOT exceed 10 mmol/L per day total correction 1
- Do NOT exceed 8 mmol/L in first 24 hours 1
- Rapid correction >1 mmol/L/hour should be reserved ONLY for acute hyponatremia (<48 hours duration) with severe symptoms 1
Chronic hyponatremia (>48 hours) must NOT be rapidly corrected due to high risk of osmotic demyelination syndrome 1. Registry data shows overly rapid correction occurred in 10.2% of patients 2.
Treatment Efficacy Data
Real-world registry data from 1,524 patients reveals important limitations of common therapies: 2
- Fluid restriction failed to increase sodium ≥5 mmol/L in 55% of monotherapy episodes 2
- Isotonic saline failed in 64% of cases 2
- Hypertonic saline and tolvaptan produced the highest mean rates of sodium change (3.0 mEq/L/day) 2
- 75% of patients were discharged still hyponatremic (sodium <135 mmol/L) 2
Special Considerations
Subarachnoid hemorrhage patients: Fluid restriction is contraindicated due to increased risk of cerebral infarction (21 of 26 fluid-restricted SAH patients developed cerebral infarction in one study) 1. These patients should receive more aggressive sodium and volume replacement 1.
Treatment threshold: Initiate workup and treatment when serum sodium falls below 131 mmol/L 1. Continue treatment until sodium reaches ≥131 mmol/L 1.
Monitoring: Reassess clinical status and biochemistry regularly, as the etiology of hyponatremia is frequently multifactorial and management may need to evolve during a single treatment episode 4.